Topical Melatonin for Hair Loss: What the Research Actually Shows
Published by AmpleLab Research
Melatonin is best known as the hormone that regulates sleep, but a separate line of research, running for more than two decades, has investigated it as a topical treatment for hair loss. Unlike many trending hair ingredients, topical melatonin has an unusually well-documented evidence base: it has been tested in a randomised, placebo-controlled trial, a rarity in this category, and was formally reviewed for safety by the EU's Scientific Committee on Consumer Safety in 2010.
This article covers what the clinical evidence actually demonstrates, how melatonin is thought to act on the hair follicle, the concentration and regulatory picture in the UK and EU, and where the evidence base is thinner than marketing for melatonin-containing hair products sometimes implies.
The strongest single piece of evidence is a double-blind, randomised, placebo-controlled trial in 40 women with androgenetic or diffuse hair loss, who applied a 0.1% melatonin solution or placebo to the scalp once daily for six months. Melatonin produced a significant increase in occipital anagen hair rate compared with placebo. A significant increase in frontal anagen rate was also observed, but only in the subgroup with diffuse alopecia, not in those with androgenetic hair loss specifically. No study, including this one, has demonstrated that melatonin's effect translates into efficacy comparable to established treatments such as minoxidil.
40 women with diffuse or androgenetic hair loss applied a 0.1% melatonin solution or placebo once daily to the scalp for six months, with trichogram assessment of anagen and telogen hair rate. Melatonin significantly increased occipital anagen hair rate in the androgenetic hair loss group (n=12; P=0.012) compared with placebo. Blood samples were taken throughout to monitor effects on endogenous melatonin.
Caveat: This is the best-controlled study in the melatonin literature, but the concentration used, 0.1%, is roughly 30 times higher than the concentration reviewed and cleared by EU regulators for cosmetic use, a distinction covered further down.
A 2012 review by the same research group summarised five clinical studies of a 0.0033% topical melatonin cosmetic solution, all conducted at lower concentration than the 2004 trial above and mostly without a placebo arm. An observational study in 30 men and women reported a significant reduction in the severity of hair loss after 30 and 90 days based on investigator and patient questionnaires. A TrichoScan-based study in 35 men with androgenetic alopecia found a significant increase in hair density, 29% at three months and 41% at six months, in 54.8% to 58.1% of participants. A separate study in 60 men and women found a significant reduction in shedding in women, while hair loss in men remained essentially unchanged. The largest study, a three-month multi-centre observational study spanning more than 1,800 volunteers, reported a marked improvement in hair pull test results alongside a reduction in seborrhoea and seborrhoeic dermatitis of the scalp.
Caveat: With the exception of the pharmacodynamic component, these are pre-post observational studies without a placebo comparator, evaluated by investigator and patient questionnaires or a single imaging method. That study design cannot rule out placebo response, regression to the mean, or seasonal variation in shedding, all of which are known confounders in hair loss research. Tolerability across all five studies was good.
A 2023 systematic review of the melatonin and hair growth literature, searching PubMed, Google Scholar, and Cochrane through 2022, concluded that the available evidence supports melatonin use to facilitate scalp hair growth, particularly in men with androgenetic alopecia, while explicitly calling for studies with larger patient numbers and clearer investigation of the underlying mechanism.
Caveat: A systematic review is a synthesis of the same limited body of research described above, not an independent replication. It strengthens confidence that the existing findings are being read consistently across the field, but it does not add new controlled data.
The honest position
The evidence base for topical melatonin is genuinely more substantial than for most trending hair ingredients, and includes one properly randomised, placebo-controlled trial. But the total number of controlled participants remains small, most of the supporting studies are open-label or pre-post observational designs, and the field's own reviewers are calling for standardised trials rather than treating the question as settled. This is a promising, plausible intervention with real regulatory and clinical scrutiny behind it, not a proven treatment on the level of minoxidil.
Melatonin is a potent free radical scavenger and antioxidant, and this property is the mechanism most consistently cited across the research. Hair follicles are metabolically demanding structures that generate reactive oxygen species as a normal by-product of the growth phase, and oxidative stress has been implicated in premature follicle ageing and cycle disruption. Melatonin's antioxidant activity, along with anti-inflammatory effects observed in preclinical models, is proposed to protect follicle cells from this cumulative damage.
A receptor-mediated pathway is also biologically plausible. The MT1 membrane receptor has been detected directly in human hair follicle keratinocytes and in the fibroblasts of the dermal hair papilla, and an aberrant form of the MT2 receptor has also been identified in dermal papilla fibroblasts. In the C57BL/6 mouse model, MT2 expression in skin has been shown to vary in a hair cycle-dependent manner, which raises the possibility that melatonin signalling could influence the human hair cycle in a similar way, though this has not been directly confirmed in human tissue.
It is worth being direct about the limits of this picture: the researchers behind the most-cited clinical review on the subject describe the mechanism as not yet clarified in detail, characterising it as "highly likely" to involve a melatonin receptor-mediated antiandrogenic effect, an antioxidative effect, or both. That is a considerably more tentative statement than the confidence with which melatonin is sometimes marketed in commercial hair products.
In 2010, the EU's Scientific Committee on Consumer Safety (SCCS) published a formal opinion on melatonin following a request for safety evaluation at a maximum concentration of 0.0033% w/w in hair products. The committee reviewed acute and repeated-dose toxicity, genotoxicity, skin irritation and sensitisation, phototoxicity, and dermal absorption data, and concluded that the use of melatonin in hair products at 0.0033% does not pose a risk to consumer health. This opinion remains the primary regulatory reference point for melatonin as a cosmetic ingredient in the UK and EU.
A detail worth being precise about: the SCCS safety opinion and the strongest efficacy trial were not conducted at the same concentration.
In practice, this means a buyer choosing a melatonin hair product faces a genuine trade-off rather than a simple "more is better" decision. Products formulated at 0.0033% sit on the concentration the EU regulator has specifically assessed as safe, but most of the efficacy evidence at that exact concentration comes from open-label studies without a placebo control. Products formulated at or near 0.1% align with the strongest efficacy trial available, but that trial's concentration falls outside the specific range the SCCS opinion covers, meaning less formal regulatory scrutiny has been applied at that higher level. Neither position is wrong; they simply optimise for different things, and a transparent product should state its concentration on the label so buyers can make that trade-off knowingly, rather than leaving it undisclosed.
Melatonin is listed in the CosIng database with an antioxidant function, and its use in cosmetics is not restricted by concentration limits in the way that, for example, certain preservatives or UV filters are under Annex V and Annex VI of the EU Cosmetic Regulation. The SCCS opinion is a safety clearance for the ingredient at a specific tested concentration, not a blanket concentration ceiling, but formulators working meaningfully above the reviewed level are operating with less directly applicable safety data behind them.
Every study in the melatonin hair loss literature used once-daily evening application, generally before bedtime. This timing tracks the natural circadian rise in endogenous melatonin rather than reflecting a demonstrated requirement that the topical application must coincide with the body's own melatonin secretion; no study has directly tested whether morning application changes outcomes. Evening use is nonetheless the only protocol with any clinical data behind it, so it is the reasonable default for anyone trying the ingredient.
The evaluation window in the underlying studies ran from 90 days at the shortest to six months at the longest, consistent with the general timeline for topical hair interventions covered in the article on how long before you see results from a hair loss serum. Assessing melatonin's effect before three months have passed is not consistent with how it has actually been studied.
No published study has examined topical melatonin combined with minoxidil, finasteride, dutasteride, or copper peptides in the same protocol. This is a genuine evidence gap rather than a reason to avoid combining it; melatonin's proposed mechanism, primarily antioxidant and possibly receptor-mediated, does not obviously overlap with the vascular and DHT-suppression pathways covered in the articles on the vascular hypothesis and DHT and the follicle. But mechanistic plausibility for compatibility is not the same as clinical confirmation that layering these actives is safe or additive in effect.
Across the studies reviewed by the SCCS, topical melatonin at 0.0033% was consistently well tolerated. A local lymph node assay found no evidence of skin sensitisation, and occlusive patch testing classified the finished product as non-irritating. In use studies, a minority of participants reported mild stinging, itching, or temporary redness; none of the studies reported serious adverse events.
Topical application does result in measurable systemic absorption; this is a genuine pharmacokinetic finding, not a theoretical concern. At the 0.0033% concentration and typical dosing, the resulting increase in plasma melatonin stayed within the normal physiological range seen with the body's own night-time melatonin production, and no effect on neurocognitive testing or vital signs was observed in a 14-day controlled study. Higher experimental doses applied directly to the scalp in earlier pharmacokinetic research (in the tens of milligrams, far above what any commercial 0.0033% or 0.1% product would deliver per application) did produce more substantial and sustained increases in serum melatonin, which is the underlying reason regulatory review of concentration matters here.
No chronic toxicity or carcinogenicity studies specific to topical melatonin were available to the SCCS at the time of its review, a gap the committee itself noted. Dedicated human safety data on topical melatonin during pregnancy or breastfeeding does not appear to exist; given melatonin's known hormonal activity and the absence of specific safety data at this exposure route, this is a case where checking with a doctor or midwife before use is the appropriate precaution rather than an overcautious one. Anyone already taking oral melatonin for sleep should also be mindful that adding a topical source increases total systemic exposure in a way that has not been specifically studied.
Topical melatonin is not positioned in the research literature as a replacement for treatments with a substantially larger evidence base, such as topical minoxidil, covered in detail in the article on minoxidil for hair loss. Its proposed antioxidant and receptor-mediated mechanisms are also mechanistically distinct from DHT suppression and vascular-activity pathways, meaning it addresses a different piece of the biology rather than competing directly with those approaches.
For a broader framework on how different actives with different mechanisms can be sequenced or combined, see how to build a hair loss protocol. That framework, not this article, is the right place to work through whether and how melatonin might fit alongside other treatments for a specific situation.
Does topical melatonin actually regrow hair?
The evidence suggests melatonin can improve hair-growth-related measures such as anagen rate, shedding, and hair density, including a statistically significant result against placebo in the best-controlled trial. But the available studies, most of which are open-label and without a placebo comparator, are not sufficient to establish topical melatonin as a proven hair-regrowth treatment in the way minoxidil is.
What concentration of melatonin should I look for in a hair product?
There is no single correct answer. 0.0033% is the concentration formally reviewed and cleared for safety by the EU's Scientific Committee on Consumer Safety, and is the concentration used in most of the observational efficacy studies. 0.1% is the concentration used in the strongest randomised controlled trial. A transparent brand should state its concentration on the label regardless of which figure it uses, since an undisclosed concentration cannot be evaluated against either evidence base.
Is topical melatonin safe to use?
At the concentrations studied, the safety data reviewed by EU regulators is reassuring: non-irritating, non-sensitising, and associated with only mild, infrequent side effects such as stinging or itching in a minority of users. Some systemic absorption occurs, but plasma melatonin increases at 0.0033% stayed within the normal physiological range in controlled testing. Chronic-use and pregnancy-specific human safety data are not currently available, which is worth factoring into any decision to use it during pregnancy or breastfeeding.
Will applying melatonin to my scalp affect my sleep?
At the low concentrations used in hair products, controlled studies found no significant effect on endogenous melatonin's normal circadian pattern and no measurable effect on neurocognitive or psychomotor testing. This is a different context from oral melatonin supplements taken specifically to influence sleep, which use substantially higher doses designed to raise plasma melatonin well above baseline.
Can I use topical melatonin alongside minoxidil or other hair treatments?
No published study has directly tested this combination. Melatonin's proposed mechanism does not obviously conflict with minoxidil's vascular activity or with DHT-suppressing treatments, which suggests reasonable mechanistic compatibility, but that is not the same as clinical evidence that combining them is safe or produces an additive benefit. Anyone building a multi-active protocol should discuss it with a prescriber, particularly if any of the other actives are prescription medications.
How long before I would see results from topical melatonin?
The published studies assessed outcomes at 30 and 90 days at the earliest, with the strongest trial running a full six months. Assessing results before three months of consistent evening application is not supported by how the ingredient has actually been studied.
This article is provided for educational purposes and does not constitute medical advice. If you are pregnant, breastfeeding, or taking oral melatonin or other sleep medication, consult a qualified healthcare professional before using topical melatonin. AmpleLab products are cosmetic formulations and are not intended to diagnose, treat, cure, or prevent any condition.
AmpleLab.